Assess whether pediatric studies are necessary or waivable (504dda)

Situation

Clinical and Evidence Strategy work in a 505(b)(2) program relying on literature plus a bridging study now turns on pediatric studies are necessary because a pediatric ethicist objecting to the proposed design put advisory-committee question list that exposes a weak secondary endpoint in play. Pediatric-plan strategist should say what advisory-committee question list that exposes a weak secondary endpoint proves.

Decision

Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Pediatric studies are necessary / Waivable using advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• A pediatric ethicist objecting to the proposed design is noise around an already-controlled Clinical and Evidence Strategy process in a 505(b)(2) program relying on literature plus a bridging study, given advisory-committee question list that exposes a weak secondary endpoint.
• A pediatric ethicist objecting to the proposed design is the event in advisory-committee question list that exposes a weak secondary endpoint that forces Pediatric studies are necessary for pediatric-plan strategist under Pharma & Life Sciences.
• Advisory-committee question list that exposes a weak secondary endpoint shows a one-file miss after a pediatric ethicist objecting to the proposed design, not a Clinical and Evidence Strategy program failure.
• Advisory-committee question list that exposes a weak secondary endpoint cannot decide pediatric studies are necessary yet after a pediatric ethicist objecting to the proposed design; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read advisory-committee question list that exposes a weak secondary endpoint against a pediatric ethicist objecting to the proposed design and write the one fact that would move pediatric studies are necessary for pediatric-plan strategist.